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Atopic dermatitis (AD) is a chronic inflammatory
skin disease. Here, we show that phospholipase C-
b3 (PLC-b3)-deficient mice spontaneously develop
AD-like skin lesions and more severe allergen-
induced dermatitis than wild-type mice. Mast cells
were required for both AD models and remarkably
increased in the skin of Plcb3/ mice because of
the increased Stat5 and reduced SHP-1 activities.
Mast cell-specific deletion of Stat5 gene ameliorated
allergen-induced dermatitis, whereas that of Shp1
gene encoding Stat5-inactivating SHP-1 exacer-
bated it. PLC-b3 regulates the expression of
periostin in fibroblasts and TSLP in keratinocytes,
two proteins critically involved in AD pathogenesis.
Furthermore, polymorphisms in PLCB3, SHP1,
STAT5A, and STAT5B genes were associated
with human AD. Mast cell expression of PLC-b3
was inversely correlated with that of phospho-
STAT5, and increased mast cells with high levels
of phospho-STAT5 were found in lesional skin of
some AD patients. Therefore, STAT5 regulatory
mechanisms in mast cells are important for AD
pathogenesis.366 Cell Reports 6, 366–376, January 30, 2014 ª2014 The AuthorsINTRODUCTION
Atopic dermatitis (AD) is a chronic or chronically relapsing
inflammatory skin disease. Although the etiology of AD is not
completely understood, numerous studies suggest that immune
dysregulation and impaired skin barrier function underlie the
disease (Bieber, 2008; Boguniewicz and Leung, 2011).
Epidermal overexpression of thymic stromal lymphopoietin
(TSLP), a TH2-promoting cytokine (Liu, 2006; Ziegler and Artis,
2010), seems to be a major mechanism for AD development
(Li et al., 2005; Soumelis et al., 2002; Yoo et al., 2005). Periostin,
an av integrin-interacting matricellular protein (Hamilton, 2008;
Ruan et al., 2009), recently emerged as another mediator for
AD that induces TSLP production from keratinocytes (Masuoka
et al., 2012). A mouse AD model (Spergel et al., 1998) induced
by epicutaneous treatment of ovalbumin revealed the involve-
ment of TH2, TH1, and TH17 cytokines and other factors
(Jin et al., 2009a). Another model (Kawakami et al., 2007)
induced by allergen (extract of Dermatophagoides farinae, Der
f) and staphylococcal enterotoxin B (SEB) also showed the
requirement of mast cells and T cells as well as TSLP receptor
(TSLPR) (Ando et al., 2013).
Phospholipase C (PLC) is a family of enzymes that catalyze
the hydrolysis of phosphatidylinositol 4,5-bisphosphate in
order to generate diacylglycerol and inositol 1,4,5-trisphosphate
(Suh et al., 2008). Independent of its enzymatic activity, PLC-b3
inhibits the proliferation of hematopoietic stem cells (HSCs)
Figure 1. Plcb3/ Mice Spontaneously
Develop AD-like Skin Lesions in a Mast
Cell-Dependent Manner
(A) Kaplan-Meier plots for dermatitis development
in Plcb3/ mice (n = 21).
(B) Note the eczematous skin lesions and hair loss
in periocular areas, cheeks, ears, neck, and flanks
in a 10-month-old Plcb3/ mouse.
(C) Histology of healthy (WT) and skin lesions
(Plcb3/) in ear. Scale bar, 100 mm.
(D) Graphic representation of histological analysis
of ear skin lesions of 8- to 10-month-old WT
and Plcb3/mice. Neutrophils (Neut), eosinophils
(Eos), and mast cells (MC) were enumerated
in H&E-, Congo-red- and Toluidine-blue-stained
preparations, respectively. Immunofluorescence
staining was performed to detect CD4+, CD8+, and
F4/80+ (Mf) cells. Data represent mean ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001 versus WT mice
by Student’s t test. Similar results were obtained in
lesional skin in cheeks and neck (data not shown).
HPF, high-power field.
(E) Serum IgE levels were increased in 8- to 10-month-old Plcb3/ mice. Data represent mean ± SEM.
(F) Correlation between serum IgE levels and numbers of body parts with skin lesions (see the legend for B for eczematous body parts). r2 = 0.78,
p < 0.0001, Pearson’s correlation.
(G) Incidence of skin lesions in Plcb3/ (KO), Plcb3/;KitW-sh/W-sh (KO;Wsh), Plcb3/;TCRb/ (KO;TCRb-) and Plcb3/;mMT/mMT (KO;mMT) mice for
12 months.
Results in (E) and (F) are representative of two independent experiments using three to six mice per group. See also Figure S1.and myeloid cells by interacting with SH2-domain-containing
protein phosphatase 1 (SHP-1) and signal transducer and
activator of transcription 5 (Stat5) and augmenting the dephos-
phorylating activity of SHP-1 toward Stat5, leading to the
inactivation of Stat5 (Xiao et al., 2009).
The present study demonstrated that PLC-b3-deficient mice
spontaneously develop AD-like skin lesions. We investigated
the cellular and molecular mechanisms for spontaneous and
allergen-induced AD-like dermatitis in Plcb3/ mice and their
clinical relevance to human AD.
RESULTS
PLC-b3-Deficient Mice Spontaneously Develop Mast
Cell-Dependent AD-like Dermatitis
Young (4- to 10-week-old) Plcb3/ mice displayed no obvious
abnormalities in their phenotype. By contrast, a majority of
older mice developed eczematous skin lesions and hair loss
in their periocular areas, cheeks, ears, neck, and trunk (Figures
1A and 1B). The lesions showed hyperkeratosis, thickened
epidermis and dermis, and infiltration of T cells, mast cells,
macrophages, eosinophils, and neutrophils in the dermis (Fig-
ures 1C and 1D). Eczematous Plcb3/ mice had high levels of
serum immunoglobulin (Ig) E and IgG1, whereas dermatitis-free
young Plcb3/ mice had low IgE levels (Figures 1E and S1A).
There was a good correlation between IgE levels and numbers
of the involved body parts (Figure 1F). Transepidermal water
loss (TEWL) increased only after dermatitis development
(Figure S1B), suggesting that skin barrier function was not
primarily impaired in Plcb3/ mice.
No Plcb3/;KitW-sh/W-sh mice (n = 24) deficient in mast
cells developed skin lesions during an observation period ofC12 months (Figure 1G). By contrast, skin lesions were observed
in a majority of ab T cell-deficient Plcb3/ (Plcb3/;TCRb/)
mice and B cell-deficient Plcb3/;mMT/mMT mice. These
results suggest that mast cells, but not ab T or B cells, are
indispensable for the spontaneous development of skin lesions
in Plcb3/ mice.
Plcb3/ Mice Develop Severe Allergen-Induced
Dermatitis
Der f/SEB-induced dermatitis is dependent on mast cells and
T cells, but not B cells or eosinophils (Ando et al., 2013). Epicuta-
neous treatment with Der f and SEB of young (5- to 11-week-old)
Plcb3/ mice, which did not show any skin lesions before
experiment, induced more severe skin lesions with thicker
epidermis and dermis and higher levels of mast cell and neutro-
phil infiltration, compared to WT mice (Figures 2A–2E). Although
Der f/SEB treatment increased serum levels of IgE and IgG1,
some of which recognized Der f antigens, their levels were
comparable in WT and Plcb3/ mice (Figures S2A and S2B).
As shown previously (Ando et al., 2013), mast cell-deficient
KitW-sh/W-sh mice showed less severe Der f/SEB-induced skin
lesions than did WT mice. Mast cell deficiency also resulted
in less severe skin lesions in Der f/SEB-treated Plcb3/;
KitW-sh/W-sh mice, compared to Plcb3/ mice (Figures 2F and
2G). Moreover, engraftment of Plcb3/ bone-marrow-derived
mast cells (BMMCs) into the back skin of Plcb3/;KitW-sh/W-sh
mice restored the severity of Der f/SEB-induced dermatitis to
levels in Plcb3/ mice (Figures 2F–2H). Therefore, similar to
spontaneous dermatitis in Plcb3/ mice, mast cells contribute
substantially to the development of Der f/SEB-induced derma-
titis in these mice. Consistent with increased Der f-specific IgE
levels in WT and Plcb3/ mice, FcεRI-deficient mice exhibitedell Reports 6, 366–376, January 30, 2014 ª2014 The Authors 367
Figure 2. Mast Cells Significantly Contri-
bute to the Increased Severity of Der f/SEB-
Induced Skin Lesions in Plcb3/ Mice
(A) AD-like skin lesions were induced as described
previously (Kawakami et al., 2007). D/B, treatment
with Der f and SEB. The periods when Der f/SEB-
treated back skin is occluded with Tegaderm are
also shown.
(B) AD scores on day 24 with WT and Plcb3/
mice.
(C) H&E staining of lesional skins in WT and
Plcb3/ (KO) mice.
(D) Thicknesses of epidermis and dermis at basal
and Der f/SEB (D/B)-treated levels were measured
on H&E-stained lesional skins. Results in (B)–(D)
are representative of three independent experi-
ments using five to eight mice per group.
(E) Histologic analysis of Der f/SEB-induced
dermatitis.
(F and G) Dermatitis was induced in WT,
KitW-sh/W-sh (Wsh), Plcb3/ (KO) and Plcb3/;
KitW-sh/W-sh (KO;Wsh) mice. A group of
Plcb3/;KitW-sh/W-sh mice received BMMCs
derived from Plcb3/ mice 6 weeks before Der
f/SEB treatment. (F) AD scores on day 24.
(G) Histologic analysis of dermatitis. Data repre-
sent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001
versus WT mice or indicated pairs by Student’s
t test or ANOVA; ##, p < 0.01 versus naive mice.
(H) Mast cells were quantified on Toluidine-blue-
stained skin tissues. HPF, high-power field.
Results in (F)–(H) are representative of two inde-
pendent experiments using six mice per group.
See also Figure S2.less severe skin lesions in FceRIa/ and FceRIa/;Plcb3/
mice than the respective control FcεRI-sufficient mice (Fig-
ure S2C). These results indicate that FcεRI is required for full-
blown allergen-induced dermatitis.
Plcb3/ Mast Cells Are Hypersensitive to Interleukin-3
Mast cells are derived from HSCs via bipotent basophil/mast
cell progenitors (BMCPs) and mast cell progenitors (MCPs)
(Arinobu et al., 2005; Chen et al., 2005). Consistent with the
increase in mast cells in the skin and gastrointestinal tract
(data not shown), the numbers of BMCPs in spleen and
MCPs in bone marrow were increased in young (6- to 10-
week-old) Plcb3/ mice (Figure S3A). Consistent with these
in vivo results, 10-fold or more mast cells were generated
from bone marrow cells of Plcb3/ mice in interleukin (IL)-3-
containing medium, compared to WT cells (Figure 3A),
although expression levels of FcεRI and c-Kit were similar in
both BMMCs (Figure 3B). IL-3-induced proliferation was 2- to
3-fold higher in Plcb3/ than in WT BMMCs (Figure 3C),
whereas stem cell factor (SCF)-induced proliferation was
similar in the two genotypes. Plcb3/ BMMCs migrated
more vigorously toward IL-3 than WT cells (Figure 3D). On
the other hand, growth factor withdrawal induced similar rates
of apoptotic cell death in WT and Plcb3/ BMMCs (data not
shown). These results suggest that the increased proliferation
and chemotaxis in response to IL-3 could be the major mech-
anisms for the increased mast cells in Plcb3/ mice. This IL-3368 Cell Reports 6, 366–376, January 30, 2014 ª2014 The Authorshyperresponsiveness seems due to increased IL-3 receptor
(IL-3R) signaling downstream of the receptor, given that
expression of IL-3R in mast cells and that of IL-3 mRNA in
skin tissues were comparable between WT and Plcb3/ mice
(Figures S3B and S3C).
PLC-b3 Inhibits Stat5 Activity in Mast Cells by
Interacting with SHP-1 and Stat5
PLC-b3 interacts with Stat5 and SHP-1 to form the multimole-
cular SPS complex, and juxtaposition of SHP-1 and Stat5 via
interactions with PLC-b3 enhances the catalytic activity of
SHP-1 to dephosphorylate Stat5 (Xiao et al., 2009; Yasudo
et al., 2011). As shown for Plcb3/ HSCs (Xiao et al., 2009),
IL-3-induced phosphorylation of Stat5 at Tyr694, the phospho-
rylation site critical for its activation (Gouilleux et al., 1994),
was enhanced in Plcb3/ BMMCs (Figure 3E). Furthermore,
phosphorylation of SHP-1 at Tyr536, which is necessary for effi-
cient interaction with Stat5 (Xiao et al., 2010), was abolished
in Plcb3/ cells.
Introduction of dominant-negative Stat5 drastically inhibited
proliferation of Plcb3/ BMMCs (Figure 3F). Transduction
with WT SHP-1 restored SHP-1 phosphorylation and inhibited
IL-3-induced Stat5 phosphorylation (Figure 3G) and mast cell
proliferation (Figure 3F). These results show that IL-3 hyper-
responsiveness caused by PLC-b3 deficiency depends on
increased Stat5 activity and reduced SHP-1 activity. Given
the comparable expression of IL-3 and IL-3R between WT and
Figure 3. Plcb3/ Mast Cells Are Hypersensitive to IL-3 Stimulation
(A) Bone marrow cells derived from WT or Plcb3/ mice were cultured in IL-3-containing medium for the indicated periods. Live cells were counted.
(B) Greater than 98% of 5 week cultured BMMCs expressed c-Kit and FcεRI. Results in (A) and (B) are representative of at least ten experiments using three to
four mice per group.
(C) BMMCs were depleted of IL-3 for 8 hr and cultured in the indicated concentrations of IL-3 or SCF for 36 hr. DNA synthesis was measured by [3H]thymidine
incorporation during the last 18 hr of culture.
(D) Chemotaxis of BMMCs toward IL-3 or SCFwas assayed in Transwell for 8 hr. Results in (C) and (D) are representative of two experiments using threemice per
group.
(E) WT and Plcb3/ BMMCs were stimulated with 10 ng/ml of IL-3 for the indicated periods. Cell lysates were analyzed by SDS-PAGE followed by western
blotting using antibodies for the indicated molecules.
(F and G) WT and Plcb3/MCPs were transduced with bicistronic retroviral vectors coding for DN Stat5 (DN5), WT SHP-1, or empty vector. GFP+-transduced
cells were FACS-sorted and cultured in IL-3 (F). *p < 0.05 versus empty vector-transduced WT cells (WT [vec]) by Student’s t test. Some transduced Plcb3/
mast cells were stimulated with IL-3 and subjected to western blot analysis (G).
Results in (E)–(G) are representative of two transduction experiments. In (A), (C), (D), and (F), data represent mean ± SEM. See also Figure S3.Plcb3/ mice (Figures S3B and S3C), not only IL-3 but also
other factors that lead to Stat5 activation would contribute to
the increased mast cells in Plcb3/ mice.
Stat5 in Mast Cells Is Critical for Full Expression of
Allergen-Induced Dermatitis
The above results imply that Stat5 and SHP-1 might contribute
to dermatitis development by regulating the mast cell respon-
siveness to IL-3 (and other stimuli). To investigate this possibility
more directly, we generated mice with mast cell-specific dele-
tion of Stat5 (A and B) or Shp1 loci, termed MCDStat5 and
MCDSHP-1 mice, respectively. Loss of expression of the tar-
geted loci was confirmed by immunoblotting of neonatal skin-
derived mast cells (Figure 4A) and/or immunofluorescence
microscopy of skin mast cells (Figure S4A). Expression of Cre
recombinase driven by the Mcpt5 promoter (Scholten et al.,
2008) did not affect numbers and distributions of T cells, B cells,
or granulocytes (data not shown). Der f/SEB treatment inducedCsignificantly lower skin scores in MCDStat5 mice (Figure 4B)
with lower infiltration of neutrophils and eosinophils (Figure 4D),
but with WT levels of skin thickness (Figure 4C), compared to
control mice. By contrast, higher skin scores were observed
in MCDSHP-1 mice than in control mice (Figure S4B). There
were similar numbers of mast cells in the ears of WT,MCDStat5
(Figure 4D), and MCDSHP-1 mice (Figure S4C). Mast cells
reactive with phospho-Stat5 antibody were abundant in the
inflammatory dermis from Der f/SEB-induced dermatitis (Figures
4E and 4F), although phospho-Stat5 positive cells were not
restricted to mast cells. Further confirming the role of Stat5 in
skin inflammation, TG101348, an inhibitor of Jak2 kinase that
activates Stat5 activity (Pardanani et al., 2011), ameliorated
Der f/SEB-induced dermatitis with reduced skin thickness
and reduced numbers of mast cells, neutrophils and eosinophils
(Figures S4D–S4F). These results collectively demonstrate that
Stat5 activity in mast cells is required for full expression of
allergen-induced skin inflammation.ell Reports 6, 366–376, January 30, 2014 ª2014 The Authors 369
Figure 4. Stat5 in Mast Cells Regulates Der f/SEB-Induced Dermatitis
Dermatitis was induced with Der f/SEB inMCDStat5mice [CKO or Cre(+)] and their floxed control [fl/fl or Cre()] mice. *p < 0.05, ***p < 0.001 by Student’s t test.
(A) Western blot analysis of Stat5 in mast cells derived from neonatal skin of MCDStat5 (CKO) and control (fl/fl) mice.
(B) AD scores accumulated from four separate experiments using three to five mice per group.
(C) Thicknesses of epidermis and dermis after Der f/SEB (D/B) treatment.
(D) Histologic analysis of Der f/SEB-induced dermatitis. Data represent mean ± SEM.
(E and F) Skin sections of naive and Der f/SEB-induced (6 hr after fourth induction) dermatitis in WTmice were stained for phospho-Stat5, mMCP4, and mMCP6.
Arrowheads indicate pStat5-positive mast cells. Ep, epidermis; D, dermis; HF, hair follicle. Representative images of mast cells from three experiments are
shown in (E) and (F). See also Figure S4.TSLP Is Highly Expressed in the Epidermis and Critical
for Skin Inflammation in Plcb3/ Mice
Overexpression of TSLP in keratinocytes in transgenic mice
results in an AD-like phenotype (Li et al., 2005; Yoo et al.,
2005). TSLP, which activates Stat5 (Isaksen et al., 1999), is highly
expressed by keratinocytes in human AD (Soumelis et al., 2002)
and, along with IL-1 and TNF, induces mast cells to secrete
IL-13, IL-5, and other cytokines (Allakhverdi et al., 2007). TSLP
expression is induced by various stimuli, including allergens,
proteases, and mechanical injury (Ziegler, 2012). We next exam-
ined the role of TSLP in dermatitis in Plcb3/ mice. Similar to a
report (Bogiatzi et al., 2007), TSLP protein was highly expressed
in the epidermis of lesional skin (Figure 5A), but TSLP mRNA
levels were not increased in Plcb3/ mice (data not shown).
As expected, we observed TSLP expression in the epidermis
in Der f/SEB-treated KitWsh/W-sh mice and identically treated
WT mice. However, TSLP expression was more intense in the
thickened epidermis in the latter mice than in the former mice
(Figure S5A). It was evenmore exaggerated in Der f/SEB-treated
Plcb3/ and Plcb3/;KitW-sh/W-sh mice. We interpret that the
overexpression of epidermal TSLP in Plcb3/ and Plcb3/;
KitW-sh/W-sh mice reflects the loss of PLC-b3-mediated suppres-
sion of TSLP expression in keratinocytes (Figure S5B) in these
mice.
Importantly, no Plcb3/;TSLPR/mice lacking both PLC-b3
and TSLPR (n = 10) developed dermatitis for 12 months (Fig-
ure 5B). Consistent with the role of TSLPR in Der f/SEB-induced
dermatitis (Ando et al., 2013), Der f/SEB-induced dermatitis
was less severe in Plcb3/;TSLPR/ mice than in Plcb3/
mice (Figure 5C). Lesional skin in the former mice, which
exhibited high levels of epidermal TSLP expression (data not370 Cell Reports 6, 366–376, January 30, 2014 ª2014 The Authorsshown), had reduced numbers of eosinophils and neutrophils
(Figure 5D), but these mice had serum levels of IgE, similar to
those of Plcb3/ mice (data not shown). TSLP expression
was low in Der f/SEB-treated skin of TG101348-treated mice
(Figure S4G). Therefore, the TSLP-TSLPR axis is critically
important for both spontaneous and allergen-induced dermatitis
in Plcb3/ mice.
Proinflammatory cytokines such as TNF, in combination with
TH2 cytokines, can induce the expression of TSLP in keratino-
cytes (Bogiatzi et al., 2007). However, all Plcb3/;TNF/ mice
(n = 34) spontaneously developed dermatitis within 9 months
(Figure 5E). Granulocyte macrophage colony stimulating factor
(GM-CSF) can also activate Stat5 (Mui et al., 1995), promote
TH2 cell responses (Kusakabe et al., 2000), and might contribute
to the establishment and chronicity of AD lesions (Bratton et al.,
1995). Although GM-CSF contributed to epidermal and dermal
thickening in allergen-induced skin inflammation (T.A. and T.K.,
unpublisheddata), allPlcb3/;GM-CSF/mice (n=31) sponta-
neously developed dermatitis within 8months (Figure 5F). There-
fore, both TNF and GM-CSF were dispensable for spontaneous
skin inflammation in Plcb3/mice.
PLC-b3 Regulates Periostin Production by Fibroblasts
A recent study showed that periostin is a critical mediator for
a Der f-induced AD model and that periostin expression is
correlated with the severity of human AD (Masuoka et al.,
2012). Periostin was highly expressed in the lesional dermis of
spontaneous dermatitis in Plcb3/ mice (Figure 6A) as well
as Der f/SEB-induced dermatitis in WT and Plcb3/ mice
(Figure 6B). By contrast, its protein and mRNA expression was
reduced in Der f/SEB-induced dermatitis in mast cell-deficient
Figure 5. Role of the TSLP-TSLPR Axis in
Der f/SEB-Induced Dermatitis and Sponta-
neous Dermatitis in Plcb3/ Mice
(A) Lesional skin from 10-month-old Plcb3/mice
and healthy control (WT) were stained for TSLP
(red) and nuclei (blue).
(B) Kaplan-Meier plots for dermatitis development
in Plcb3/;TSLPR/ (n = 10).
(C) Dermatitis was induced with Der f/SEB in WT,
TSLPR/ (T/), Plcb3/ (b3/), and Plcb3/;
TSLPR/ (b3/;T/) mice.
(D) Histologic analysis of Der f/SEB-induced
dermatitis. Data represent mean ± SEM.
(E and F) Kaplan-Meier plots for dermatitis devel-
opment in Plcb3/;TNF/ (n = 34), and Plcb3/;
GM-CSF/ (n = 31) mice.
Results in (C) and (D) are representative of two
independent experiments using three to six mice
per group. *p < 0.05, **p < 0.01, ***p < 0.001 by
ANOVA. See also Figure S5.mice (Figures 6B and 6C). Consistent with the known role of
periostin in fibrosis, Masson trichrome staining confirmed
remarkable fibrosis in skin lesions of spontaneous dermatitis
(Figure S1C) and Der f/SEB-induced dermatitis (data not shown).
To further analyze periostin expression, embryonic fibroblasts
(MEFs) and NIH/3T3 fibroblasts were used. When fibroblasts
were cocultured with IgE/antigen-stimulated BMMC, periostin
secretion was increased (Figure 6D). We confirmed that IL-13,
a major cytokine produced by IgE/antigen-stimulated mast cells
(Burd et al., 1995), enhances the production and secretion of
periostin in fibroblasts (Figure 6E). These results collectively
demonstrate that mast cells can regulate periostin production
in fibroblasts.
Importantly, basal levels of periostin were remarkably higher
in Plcb3/ than in WT MEFs. Therefore, constitutive expression
of periostin appeared to be negatively regulated by PLC-b3.
Costimulation ofWT, but notPlcb3/, MEFswith TSLP inhibited
IL-13-induced periostin production/secretion (Figure 6F). This
result suggests the presence of feedback inhibition in the skin
for fibroblasts’ periostin production by TSLP, which can be
induced in keratinocytes by periostin (Masuoka et al., 2012),
and this feedback inhibition is lost in Plcb3/ MEFs. We also
found that TSLP mRNA expression is higher in Plcb3/ than in
WT keratinocytes (Figure S5B), consistent with increased TSLP
expression in the epidermis of lesional skin ofPlcb3/mice (Fig-
ure 5A). These results not only add a cellular component (i.e.,
mast cells) to the hypothetical vicious cycle of skin inflammation
consisting of TH2 cytokines (from TH2 cells)-periostin (from fibro-
blasts)-TSLP (fromkeratinocytes) (Masuoka et al., 2012), but alsoCell Reports 6, 366–376show that PLC-b3 intrinsically regulates
periostin production in fibroblasts and
TSLP expression in keratinocytes.
Association of the SPS Complex
Genes and Mast Cell-Expressed
Phospho-STAT5 with Human AD
The clinical relevance of Der f/SEB-
induced dermatitis was supported bysimilarity in gene expression profiles between this dermatitis
and human AD (Ando et al., 2013). Gene expression profiles in
spontaneous dermatitis in Plcb3/mice were also more similar
to those in humanAD than those in human psoriasis (Table S1). In
light of the strong clinical relevance of the two dermatitis models
and functional relationship among PLC-b3, STAT5, and SHP-1
in mast cells, we genotyped single nucleotide polymorphisms
(SNPs) for these genes (Table S2) in AD populations (Table S3).
The AD patients were stratified as ADEH+ and ADEH based
on those who suffered eczema herpeticum and those who did
not, respectively. Eczema herpeticum is a severe disseminated
herpes virus infection that occurs at skin lesions of AD and other
conditions (Wollenberg et al., 2003); ADEH+ patients suffer more
severe dermatitis than ADEH patients (Beck et al., 2009).
Among the PLCB3 SNPs tested, rs2244625 was associated
with risk of ADEH in European American subjects (Table S4).
Furthermore, a nonsynonymous SNP (rs35169799) was signifi-
cantly associated with decreased levels of IgE among controls
but not among AD subjects (Figure S6A). Table S4 shows that
STAT5B SNP rs9900213 and SHP1 SNP rs7310161 were sig-
nificantly associated with the risk of AD among European
American subjects. One STAT5A SNP (rs16967637) and
four SHP1 SNPs were associated with the severity of AD
among African Americans. No AD-associated SNPs except for
rs35169799 change protein structures.
Finally, we found that mast cells are more abundant in the
dermis of AD lesions than in that of nonlesional skin of AD
patients or healthy individuals (Figures 7A and 7B). More
importantly, mast cells were abundantly detected with higher, January 30, 2014 ª2014 The Authors 371
Figure 6. Regulation of Periostin Produc-
tion in Fibroblasts
(A) Lesional skin of spontaneous dermatitis in
Plcb3/mice (KO) and normal skin fromWT mice
(WT) were stained for periostin (red) and nuclei
(blue). Right panels show control stainings without
antiperiostin antibody.
(B) Periostin was stained before (naive) and after
Der f/SEB induction of dermatitis (induced) in WT,
KitW-sh/W-sh (Wsh), Plcb3/ (KO), and Plcb3/;
KitW-sh/W-sh (KO;Wsh) mice. Borders of epidermis,
dermis and subcutaneous fat tissues are indicated
by dotted lines.
(C) Periostin mRNA expression in Der f/SEB-
treated skin was quantified by qPCR.
(D) NIH/3T3 cells were incubated with or without
IgE-sensitized BMMCs in the presence or absence
of antigen.
(E and F) WT and Plcb3/ MEFs were stimulated
by the indicated concentrations of IL-13 in the
absence (E) or presence (F) of 0, 10, or 100 ng/ml
of TSLP for 24 hr.
Results in (A)–(C) are representative of three
experiments using three to five mice per group.
Periostin protein in culture supernatants and
lysates of the cells was analyzed by western
blotting. *p < 0.05, **p < 0.01, ***p < 0.001 by
ANOVA. In vitro experiments with results similar
to (D)–(F) were performed two to four times.
See also Figure S7.nuclear intensities of phospho-STAT5 staining in lesional skin
of some AD patients (Figures 7C–7E). Nuclear STAT5 phos-
phorylation in mast cells was correlated with skin mast cell
numbers (Figure S6B) and inversely correlated with PLC-b3
expression in mast cells (Figures S6C–S6F). The above SNP
and immunofluorescence data support the idea that dysregula-
tion of the SPS complex leading to STAT5 activation is involved
at least in some cases of human AD.
DISCUSSION
In this study, we showed that mast cells, but not ab T or B cells,
are required for spontaneously occurring dermatitis in Plcb3/
mice. We show a mast cell-dependent naturally occurring AD
model (Kawakami et al., 2009), despite the limitations of Kit
mutant mice as a model of mast cell deficiency (Rodewald and
Feyerabend, 2012). Plcb3/ mast cells were hyperresponsive
to IL-3 due to increased Stat5 activity, which could be antago-
nized by PLC-b3 and SHP-1. These in vitro results support
the in vivo anti-inflammatory role of PLC-b3 and SHP-1 that372 Cell Reports 6, 366–376, January 30, 2014 ª2014 The Authorsregulate the proliferative and chemotactic
behavior of mast cells by controlling Stat5
activity. Characterization of spontaneous
dermatitis in Plcb3/ mice was comple-
mented by allergen-induced dermatitis
experiments, as the particular importance
of Stat5 regulation in mast cells was
demonstrated by alleviated allergen-
induced dermatitis in mice lacking Stat5in mast cells and by efficient suppression of allergen-induced
dermatitis by chemical inhibition of Stat5 activity. Spontaneous
dermatitis in Plcb3/ mice depended on the TSLP/TSLPR
axis, which uses Stat5 as a critical signal transducer (Isaksen
et al., 1999). Thus, Stat5 activation is required for the develop-
ment of both spontaneous and allergen-induced dermatitis.
Human data suggest that STAT5 activating pathways in mast
cells are operational in a subset of AD patients.
Various studies suggest the role of T cells in AD pathogenesis
(Jin et al., 2009a; Kawakami et al., 2009). Skin inflammation
in our Der f/SEB model requires ab T cells (Ando et al., 2013),
in line with the widely accepted scenario for AD development
(Bieber, 2008; Boguniewicz and Leung, 2011): impaired skin
barrier function allows allergens easy access to the inside of
skin; allergens are taken up by Langerhans cells and dermal
dendritic cells, and these cells migrate and mature to present
allergens to naive helper T cells in lymph nodes; activated and
differentiated TH2 cells migrate back to skin sites re-exposed
to allergens; these effector TH2 cells recruit mast cells, eosino-
phils, and other granulocytes in order to cause tissue damages.
Figure 7. Increased Numbers of Mast Cells
with Enhanced STAT5 Phosphorylation in
Human AD Patients
(A) Lesional and nonlesional skin samples of
human AD patients were analyzed by Toluidine
blue staining. Portions indicated by rectangle are
enlarged on right panels. Red arrows indicate
mast cells.
(B) Quantification of mast cells. **p < 0.01;
***p < 0.001 by Tukey’s multiple comparison
test (ANOVA).
(C) Skin samples of human AD patients were
stained for phospho-STAT5 (red), tryptase (green),
and nuclei (blue). Representative images are
shown from patient P1.
(D and E) Nuclear phospho-STAT5 levels in mast
cells in lesional (L) and nonlesional (NL) skin
samples of human AD patients and healthy skin
(H) were measured by ImageJ software (NIH). Data
represent mean ± SEM. *p < 0.05, **p < 0.01, ***p <
0.001 versus nonlesional (NL) skin by Student’s
t test. See also Figure S6 and Tables S1–S4.Although ab T cells were dispensable for spontaneous dermatitis
in Plcb3/ mice, ab T cells seem to contribute to a severe
phenotype in this dermatitis. Thus, skin inflammation in
Plcb3/;TCRb/ mice was less prominent than that in
Plcb3/mice (data not shown). By contrast, B cells (the source
of IgE) appeared to be dispensable for both spontaneous
dermatitis and allergen-induced dermatitis, although there was
a clear correlation between IgE levels and the severity of derma-
titis. This apparent discrepancy seems to be related to the pres-
ence of both activating (FcεRI) and inhibitory (FcgRIIb) receptors
for IgE in mast cells (and other cells), given that FcεRI was
required for maximal allergen-induced skin inflammation.
Masuoka et al. (2012) recently proposed a vicious cycle for
allergic skin inflammation consisting of TH2 cytokines (from
TH2 cells)-periostin (from fibroblasts)-TSLP and other proinflam-
matory cytokines (from keratinocytes). Our Der f/SEB induction
model requires T cells for full-blown dermatitis, whereas sponta-
neous and persistent dermatitis in Plcb3/ mice does not.
The TSLP-TSLPR axis and mast cells are required for both ADCell Reports 6, 366–376models (this study; Ando et al., 2013),
whereas T cells are required only for
allergen-induced dermatitis. Therefore,
we speculate that T cells and mast cells
are required for TSLP overexpression.
Once sustained overexpression of TSLP
is established, mast cells may play a
more important role in persistent derma-
titis as the cellular source of TH2 cyto-
kines (Figure S7). Related to this network,
our current study showed that PLC-b3
can regulate activities of the cellular ele-
ments of the network, such as prolifera-
tion in mast cells, periostin expression
in fibroblasts and TSLP expression in
keratinocytes. Our data also suggest the
presence of a feedback loop for inhibitionof fibroblasts’ periostin production by TSLP, and PLC-b3 in
fibroblasts is required for this negative feedback. Among the
cytokines induced in keratinocytes by periostin, we found that
TSLP, but not TNF or GM-CSF, is important for the development
of spontaneous dermatitis in PLC-b3/ mice.
Our human data are consistent with mouse data by showing
genetic linkage with all four genes that encode components of
the SPS complex. Although IL-3 alone or IL-3 plus IL-4 cannot
induce the differentiation of human mast cells (Saito et al.,
1988), human mast cells express functional receptors for IL-3,
IL-5, and GM-CSF (Dahl et al., 2004), and, along with SCF, IL-3
can enhancemast cell growth by decreasingmast cell apoptosis
(Gebhardt et al., 2002). Interestingly, silencing of STAT5A and
STAT5B expression induced apoptosis in human mast cells
(J.K. and T.K., unpublished data). Thus, the breakdown of
PLC-b3/SHP-1-dependent suppression of STAT5 activity, which
is recruited by IL-3 or other cytokines in human mast cells, may
represent a pathogenic mechanism for human AD. Alternatively,
SPS complexes might regulate the growth properties of cell, January 30, 2014 ª2014 The Authors 373
types other than mast cells. Several cytokines including IL-5,
IL-21, IL-31, TSLP, and GM-CSF, which are implicated in AD
pathogenesis (Jin et al., 2009b; Sonkoly et al., 2006; Soumelis
et al., 2002; Yamamoto et al., 2003), utilize the JAK-STAT5
pathway for their signal transduction. Reduced expression of
PLC-b3, thus improper regulation of STAT5 activity in those
cells, would contribute to AD development. These consider-
ations provide additional reasoning for the JAK-STAT5 pathway
as a potential target of AD treatment. However, not all AD
patients showed increased expression of STAT5 phospho-
rylation in mast cells. Thus, stratification of AD by STAT5
phosphorylation and/or PLC-b3 expression may be important
for clinical application of our results.
EXPERIMENTAL PROCEDURES
Human Subjects
Two independent populations were used for genetic association analysis,
including 414 European American subjects and 323 African American
subjects. Subjects were recruited as part of the NIAID-supported Atopic
Dermatitis and Vaccinia Network (ADVN). Demographic characteristics are
presented in Table S3. AD patients and healthy individuals were also recruited
at University of California San Diego. Skin biopsies using a 4mmpunch biopsy
were performed on a lesional target site of atopic skin and a target nonlesional
site at least 4 cm from the lesional site. Normal matched control samples were
obtained from healthy donors in similar locations.
AD Diagnosis and Phenotypes
AD was diagnosed using the US consensus conference criteria (Eichenfield
et al., 2003). ADEH was defined as AD patients with at least one eczema
herpeticum episode documented either by an ADVN investigator or by another
physician confirmed by PCR detection of HSV infection, tissue immunofluo-
rescence, Tzanck smear, and/or culture. AD severity was defined according
to the ‘‘eczema area and severity index’’ (EASI), a standardized grading system
(Hanifin et al., 2001), and total serum IgE was measured using the UniCap
250 system (Pharmacia and Upjohn). Clinical characteristics are presented
in Table S3. The study was approved by the institutional review boards at
National Jewish Health in Denver, Johns Hopkins University, Oregon Health
and Science University, University of California San Diego, Children’s Hospital
of Boston, and University of Rochester. All subjects gave written informed
consent prior to participation.
Genotyping and Quality Control
A total of 22 SNPs for the four candidate genes were selected from the
HapMap (http://www.hapmap.org/) using a tagging approach: eight PLCb3
SNPs, six STAT5A SNPs, four STAT5B SNPs, and four SHP1 SNPs. The
four SNPs in STAT5B were genotyped using the custom-designed Illumina
OPA for the BeadXpress Reader System and the GoldenGate Assay with
VeraCode Bead technology according to the manufacturer’s protocol. The
rest of SNPs were genotyped and analyzed on a 7900HT Sequence Detection
System (Applied Biosystems) with Applied Biosystems Genotyper software
(SDS system, version 2.2). As part of quality control, we genotyped additional
74 SNPs identified as ancestry informative markers selected for maximal
difference between African and European populations and assessed potential
confounding factors due to population substructure using genotype data and
the STRUCTURE program (v.2.2; http://pritch.bsd.uchicago.edu/software).
Mice
Plcb3/mice were backcrossed to C57BL/6mice for 12 generations. C57BL/
6-KitW-sh/W-sh mice were bred to Plcb3/ mice, and their F1 mice were
intercrossed to generate mast cell-deficient KitW-sh/W-sh;Plcb3/ mice. Other
double-mutant mice were similarly generated. Dermatitis in both male and
female mice under SPF conditions was scored by gross appearance and
confirmed by histology. Animal experiments were approved by the Animal374 Cell Reports 6, 366–376, January 30, 2014 ª2014 The AuthorsUse and Care Committee of the La Jolla Institute for Allergy and Immunology
(LIAI) and carried out in the LIAI animal facility.
Mast Cell Engraftment
BMMCs derived from female Plcb3/ mice were transferred by intradermal
injection (4 3 106 cells in 50 ml DMEM per site, totally 20 sites distributed in
five rows down the length of shaved back skin) into 4-week-old female
Plcb3/;KitW-sh/W-sh mice.
Der f/SEB Induction of AD-like Skin Lesions
AD-like skin lesions were induced by two rounds of epicutaneous treatment of
shaved back skin of male mice with Der f and SEB as described (Kawakami
et al., 2007). AD scores are based on the severity (0, no symptoms; 1, mild;
2, intermediate; 3, severe) of four possible symptoms (redness, bleeding,
eruption, and scaling). A scientist who did not know the identities of mice
scored skin lesions.
Cultures of Mast Cells and Retroviral Transduction
Bone marrow cells or MCPs purified by fluorescence-activated cell sorting
(FACS) (Chen et al., 2005) were cultured in IL-3-containing medium. Live
cells were counted during weekly media changes. Recombinant retroviruses
were generated by transfection of Plat-E cells with pMIG vectors. Bone
marrow cells or MCPs were infected with the retroviruses, and GFP+ cells
were FACS purified and cultured.
Neonatal Skin-Derived Mast Cells
Newborn skin was incubated with 0.5% trypsin-EDTA (Invitrogen) for 1 hr, and
epidermis was removed. Separated dermis was minced and incubated in
DMEM containing 2 U/mL of Liberase TL (Roche Applied Science) and
1.6 mg/ml of hyaluronidase (Sigma-Aldrich). Dispersed cells were cultured
in RPMI1640 supplemented with 10%FCS, IL-3, and SCF. FcεRIa+ c-Kit+ cells
were sorted and subject to immunoblot analysis.
Microarray Analysis of Gene Expression
RNA preparation, microarrays, and data analysis were described previously
(Ando et al., 2013). Data have been deposited in the NCBI Gene Expression
Omnibus under accession number GSE53132.
Histology
Skin biopsies were fixed with 10% formaldehyde and embedded in paraffin.
Sections were stained with hematoxylin and eosin staining (H&E), Toluidine
blue, Congo-red, or Masson trichrome. For immunohistochemistry, skin
biopsies were immediately embedded in O.C.T. compound (Sakura Tissue-
Tek) and stored at 80C. Cryosections were fixed, and endogenous
peroxidase was quenched with 3% H2O2 in cold methanol. ABC Staining
Systems (Santa Cruz Biotechnology) were used to visualize stainings with
anti-CD4 (Santa Cruz), anti-CD8 (BD Biosciences), or anti-Mac-1 (BD Biosci-
ences) as primary antibodies. For immunofluorescence, biopsies were fixed
in 4% paraformaldehyde at 4C, washed in 10%–20% sucrose in phosphate
buffered saline, embedded in O.C.T. compound, and stored at 80C.
Cryosections were dried, rehydrated, and incubated with anti-CD4, anti-
CD8, anti-F4/80 (Abcam), or anti-TSLP (Amgen) at 4C overnight. After
washing, sections were incubated with Texas-red-conjugated goat anti-rat
IgG (Southern Biotech), and mounted with ProLong Gold antifade reagent
with DAPI (Invitrogen). For the detection of periostin and phospho-Stat5 in
mast cells, 10% formalin-fixed sections were subjected to heat-induced
antigen retrieval after deparaffinization. Antiperiostin (Masuoka et al., 2012),
anti-phospho-Stat5 (Abcam), anti-mast cell tryptase (Abcam), or anti-mMCP4
and anti-mMCP6 (Shin et al., 2006) was used as a primary antibody, in combi-
nationwith Alexa-Fluor-488-, -568-, or -647-conjugated goat anti-mouse, anti-
rat, or anti-rabbit antibody (Invitrogen) as a secondary antibody. Fluorescent
images were observed at the magnification of 400 under either Nikon Eclipse
80i fluorescence microscope or Olympus FluoView FV10i confocal laser
microscope. Human skin mast cells were counted (>100 per sample) in
rectangular regions covering the entire skin layers from the epidermis to
subcutaneous adipose tissues.
Flow cytometry
Expression of c-Kit, FcεRI, and IL-3 receptor on mast cells was analyzed using
FACSCalibur (BD Biosciences) after staining with APC-conjugated anti-c-Kit
(2B8, BD Biosciences), FITC-conjugated anti-FcεRI (MAR-1, BioLegend), or
PE-conjugated anti-iL-3 receptor (5B11, BD Biosciences).
Immunoblotting
Mast cells were stimulated with IL-3 and lysed in 1% NP-40 lysis buffer.
Lysates were analyzed by SDS-PAGE followed by electroblotting to PVDF
membranes (Millipore). Membranes were incubated with a primary antibody
and then with an HRP-conjugated secondary antibody. Antibody-bound
proteins were revealed by ECL reagent (PerkinElmer).
Statistical Analysis
For genetic analysis, logistic regression, adjusting for the first two principal
components, was used to test for association between each individual marker
(under an additive model) and disease status using PLINK software (http://
pngu.mgh.harford.edu/purcell/plink/to). To test for association between
genetic markers and total serum levels of log-adjusted IgE and log-adjusted
EASI score, we used linear regression models adjusting for confounding
variables age and gender as well as the first two principal components.
Departures from Hardy-Weinberg equilibrium at each locus were tested
with chi-square tests separately for cases and controls using PLINK. Other
statistical analyses are performed by Student’s t test, ANOVA, or Tukey’s
test as shown.
ACCESSION NUMBERS
Microarray data have been deposited in the NCBI Gene Expression Omnibus
under accession number GSE53132.
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